Psychomotor Performance, Subjective and Physiological Effects and Whole Blood Δ9-Tetrahydrocannabinol Concentrations in Heavy, Chronic Cannabis Smokers Following Acute Smoked Cannabis

Journal of Analytical Toxicology

Volumn 36, Issue 6, 2012, Pages 405-412

  Schwope, David M ^a   Bosker, Wendy M ^b   Ramaekers, Johannes G ^b   Gorelick, David A ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

11 HYDROXYDRONABINOL; CANNABIS; DRONABINOL; TETRAHYDROCANNABINOL; 11 HYDROXY DELTA(9) TETRAHYDROCANNABINOL; 11 NOR DELTA(9) TETRAHYDROCANNABINOL 9 CARBOXYLIC ACID; 11-HYDROXY-DELTA(9)-TETRAHYDROCANNABINOL; 11-NOR-DELTA(9)-TETRAHYDROCANNABINOL-9-CARBOXYLIC ACID; DRUG DERIVATIVE;

ADULT; ARTICLE; ATTENTION; BLOOD PRESSURE; BLOOD SAMPLING; BREATHING RATE; CANNABIS SMOKING; COGNITION; CRITICAL TRACKING; DIVIDED ATTENTION; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; LIKERT SCALE; MALE; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; RATING SCALE; TASK PERFORMANCE; VISUAL ANALOG SCALE; ADOLESCENT; BIOTRANSFORMATION; BLOOD; CHEMISTRY; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFECT; DRUG TOLERANCE; FORENSIC TOXICOLOGY; LIMIT OF DETECTION; METABOLISM; METHODOLOGY; MIDDLE AGED; STEREOISOMERISM; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; BIOTRANSFORMATION; COHORT STUDIES; DRUG TOLERANCE; FEMALE; FORENSIC TOXICOLOGY; HEART RATE; HUMANS; LIMIT OF DETECTION; MALE; MARIJUANA SMOKING; MIDDLE AGED; PSYCHOMOTOR PERFORMANCE; STEREOISOMERISM; SUBSTANCE ABUSE DETECTION; TETRAHYDROCANNABINOL; YOUNG ADULT;

EID: 84866776656     PISSN: 01464760     EISSN: 19452403     Source Type: Journal    
DOI: 10.1093/jat/bks044     Document Type: Article

References (42)

1. United Nations Office on Drug and Crime. (2011) UN World Drug Report, pp. 11-18.
2. Substance Abuse and Mental Health Services Administration (2010) Results from the 2009 national survey on drug use and health: National findings. Office of Applied Studies, NSDUH Series H-38A. Department of Health and Human Services (DHHS), Rockville, MD.
3. Compton, R., Berning, A. (2009) Results of the 2007 national roadside survey of alcohol and drug use by drivers. NHTSA, Washington, DC.
4. Huestis, M.A., Henningfield, J.E., Cone, E.J. (1992) Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. Journal of Analytical Toxicology, 16, 276-282.
5. Kauert, G.F., Ramaekers, J.G., Schneider, E., Moeller, M.R., Toennes, S.W. (2007) Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. Journal of Analytical Toxicology, 31, 288-293.
6. Niedbala, R.S., Kardos, K.W., Fritch, D.F., Kardos, S., Fries, T., Waga, J. et al. (2001) Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. Journal of Analytical Toxicology, 25, 289-303.
7. Matsunaga, T., Iwawaki, Y., Watanabe, K., Yamamoto, I., Kageyama, T., Yoshimura, H. (1995) Metabolism of delta-9-tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys. Life Sciences, 56, 2089-2095.
8. Watanabe, K., Yamaori, S., Funahashi, T., Kimura, T., Yamamoto, I. (2007) Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sciences, 80, 1415-1419.
9. Benowitz, N.L., Rosenberg, J., Rogers, W., Bachman, J., Jones, R.T. (1979) Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: Autonomic nervous mechanisms. Clinical Pharmacology & Therapeutics, 25, 440-446.
10. Huestis, M.A., Sampson, A.H., Holicky, B.J., Henningfield, J.E., Cone, E.J. (1992) Characterization of the absorption phase of marijuana smoking. Clinical Pharmacology & Therapeutics, 52, 31-41.
11. Milman, G., Barnes, A.J., Schwope, D.M., Schwilke, E.W., Darwin, W.D., Goodwin, R.S. et al. (2010) Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. Clinical Chemistry, 56, 1261-1269.
12. Ohlsson, A., Lindgren, J.E., Wahlen, A., Agurell, S., Hollister, L.E., Gillespie, H.K. (1980) Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clinical Pharmacology & Therapeutics, 28, 409-416.
13. Ramaekers, J.G., Moeller, M.R., van Ruitenbeek, P., Theunissen, E.L., Schneider, E., Kauert, G.F. (2006) Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: Limits of impairment. Drug and Alcohol Dependence, 85, 114-122.
14. Schwilke, E.W., Schwope, D.M., Karschner, E.L., Lowe, R.H., Darwin, W.D., Kelly, D.L. et al. (2009) Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clinical Chemistry, 55, 2180-2189.
15. Schwope, D.M., Karschner, K.L., Gorelick, D.A., Huestis, M.A. (2011) Identification of recent cannabis use: Whole blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clinical Chemistry, 57, 1406-1414.
16. Hunault, C.C., Mensinga, T.T., de Vries, I., Kelholt-Dijkman, H.H., Hoek, J., Kruidenier, M. et al. (2008) Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. Psychopharmacology (Berl), 201, 171-181.
17. Chait, L.D., Zacny, J.P. (1992) Reinforcing and subjective effects of oral delta-9-THC and smoked marijuana in humans. Psychopharmacology (Berl), 107, 255-262.
18. Curran, H.V., Brignell, C., Fletcher, S., Middleton, P., Henry, J. (2002) Cognitive and subjective dose-response effects of acute oral Delta-9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology (Berl), 164, 61-70.
19. Hall, W., Solowij, N. (1998) Adverse effects of cannabis. Lancet, 352, 1611-1616.
20. Hart, C.L., van Gorp, W., Haney, M., Foltin, R.W., Fischman, M.W. (2001) Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology, 25, 757-765.
21. Heishman, S.J., Stitzer, M.L., Bigelow, G.E. (1988) Alcohol and marijuana: Comparative dose effect profiles in humans. Pharmacololgy Biochemisty and Behavior, 31, 1-8.
22. Lamers, C.T., Ramaekers, J.G. (2001) Visual search and urban city driving under the influence of marijuana and alcohol. Human Psychopharmacology, 16, 393-401.
23. Leweke, M., Kampmann, C., Radwan, M., Dietrich, D.E., Johannes, S., Emrich, H.M. et al. (1998) The effects of tetrahydrocannabinol on the recognition of emotionally charged words: An analysis using event-related brain potentials. Neuropsychobiology, 37, 104-111.
24. Ramaekers, J.G., Berghaus, G., van Laar, M., Drummer, O.H. (2004) Dose related risk of motor vehicle crashes after cannabis use. Drug and Alcohol Dependence, 73, 109-119.
25. Ramaekers, J.G., Kauert, G., van Ruitenbeek, P., Theunissen, E.L., Schneider, E., Moeller, M.R. (2006) High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology, 31, 2296-2303.
26. Hunault, C.C., Mensinga, T.T., Bocker, K.B., Schipper, C.M., Kruidenier, M., Leenders, M.E. et al. (2009) Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology (Berl), 204, 85-94.
27. Papafotiou, K., Carter, J.D., Stough, C. (2005) The relationship between performance on the standardised field sobriety tests, driving performance and the level of delta-9-tetrahydrocannabinol (THC) in blood. Forensic Science International, 155, 172-178.
28. Ramaekers, J.G., Kauert, G., Theunissen, E.L., Toennes, S.W., Moeller, M.R. (2009) Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. Journal of Psychopharmacology, 23, 266-277.
29. Daldrup, T., Meininger, I. (1998) Begutachtung der Fahrtuchtigkeit unter Cannabis im Strafverfahren. In Berghaus, G., Kruger, H.P. (eds.) Cannabis im Strassenverkehr. Gustav Fischer Verlag, Stuttgart, Germany, pp. 181-204.
30. Menetrey, A., Augsburger, M., Favrat, B., Pin, M.A., Rothuizen, L.E., Appenzeller, M. et al. (2005) Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg delta9-THC. Journal of Analytical Toxicology, 29, 327-338.
31. Schwope, D.M., Scheidweiler, K.B., Huestis, M.A. (2011) Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 401, 1273-1283.
32. Jex, H.R., McDonnell, J.D., Phatak, A.V. (1966) A "critical" tracking ask for manual control research. IEEE Transactions on Human Factors in Electronics HFE-7, New York, NY, pp. 138-145.
33. Moskowitz, H. (1973) Laboratory studies of the effects of alcohol on some variables related to driving. Journal of Safety Research, 5, 185-199.
34. Galeazzi, R.L., Benet, L.Z., Sheiner, L.B. (1976) Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clinical Pharmacology & Therapeutics, 20, 278-289.
35. Mehmedic, Z., Chandra, S., Slade, D., Denham, H., Foster, S., Patel, A.S. et al. (2010) Potency rends of D9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. Journal of Forensic Sciences, 55, 1209-1217.
36. Cocchetto, D.M., Owens, S.M., Perez-Reyes, M., Di Guiseppi, S., Miller, L.L. (1981) Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man. Psychopharmacology (Berl), 75, 158-164.
37. Barnett, G., Chiang, C.W., Perez-Reyes, M., Ownes, S.M. (1982) Kinetic study of smoking marijuana. Journal of Pharmacokinetics and Biopharmaceutics, 10, 495-506.
38. Chiang, C.W., Barnett, G. (1984) Marijuana effect and delta-9- tetrahydrocannabinol plasma level. Clinical Pharmacology & Therapeutics, 36, 234-238.
39. Cone, E.J., Huestis, M.A. (1993) Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage. Therapeutic Drug Monitoring, 15, 527-532.
40. Bellissant, E., Sebille, V., Paintaud, G. (1998) Methodological issues in pharmacokinetic-pharmacodynamic modelling. Clinical Pharmacokinetics, 35, 151-166.
41. Mareck, U., Haenelt, N., Geyer, H., Guddat, S., Kamber, M., Brenneisen, R. et al. (2009) Temporal indication of cannabis use by means of THC glucuronide determination. Drug Test Analysis, 1, 505-510.
42. Kelly, P., Jones, R.T. (1992) Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. Journal of Analytical Toxicology, 16, 228-235.